Editas Medicine Company
Editas Medicine is engaged in discovering and developing a novel class of genome editing therapeutics.
Total Funding:
656600000
Last Funding Type:
Post-IPO Equity
Estimated Revenue:
$1M to $10M
Founded Date:
2013-01-01
Industry:
Atrificial Vectors and Immune Cells
Employee Number:
101-250
Last Funding Date:
2021-01-21
Funding Status:
IPO
Headquarters:
Cambridge, Massachusetts, United States
Investors Number:
17